Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

C. Copigneaux · SciRah

Researcher profile · Semantic Scholar

C. Copigneaux

Share profile

C. Copigneaux — researcher profile on SciRah

h-index: 11
Works: 23
Citations: 569

Most-cited papers

Phase I Trial of Weekly Tigatuzumab, an Agonistic Humanized Monoclonal Antibody Targeting Death Receptor 5 (DR5)
A. Forero-Torres, J. Shah, T. Wood, J. Posey +6 more
2010Cancer Biotherapy and Radiopharmaceuticals150 citations Open access
Semantic Scholar
Phase I Study of U3-1287, a Fully Human Anti-HER3 Monoclonal Antibody, in Patients with Advanced Solid Tumors
P. LoRusso, P. Jänne, M. Oliveira, N. Rizvi +11 more
2013Clinical Cancer Research91 citations Open access
Semantic Scholar
A Phase 1 Study of Efatutazone, an Oral Peroxisome Proliferator-Activated Receptor Gamma Agonist, Administered to Patients With Advanced Malignancies
M. Pishvaian, J. Marshall, A. Wagner, Jimmy J. Hwang +11 more
2012Cancer69 citations Open access
Semantic Scholar
Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1-2, open-label, multicohort trial.
A. Oaknin, K. Moore, T. Meyer, J. L. López-Picazo González +16 more
2024The Lancet Oncology60 citations
Semantic Scholar
Clinical Translation and Validation of a Predictive Biomarker for Patritumab, an Anti-human Epidermal Growth Factor Receptor 3 (HER3) Monoclonal Antibody, in Patients With Advanced Non-small Cell Lung Cancer
J. Mendell, D. Freeman, Wenqin Feng, T. Hettmann +10 more
2015EBioMedicine42 citations Open access
Semantic Scholar
First-in-human study of the antibody DR5 agonist DS-8273a in patients with advanced solid tumors
A. Forero, J. Bendell, Prasanna Kumar, L. Janisch +6 more
2017Investigational new drugs33 citations
Semantic Scholar
520MO Safety and efficacy of nivolumab (NIVO) ± ipilimumab (IPI) in patients (pts) with recurrent/metastatic cervical cancer (R/M Cx Ca) in checkmate 358
A. Oaknin, K. Moore, T. Meyer, J. L. González +16 more
2022Annals of Oncology28 citations Open access
Semantic Scholar
Circulating heregulin level is associated with the efficacy of patritumab combined with erlotinib in patients with non-small cell lung cancer.
K. Yonesaka, K. Hirotani, J. von Pawel, M. Dediu +3 more
2017Lung Cancer21 citations
Semantic Scholar
Phase 2 HERALD study of patritumab (P) with erlotinib (E) in advanced NSCLC subjects (SBJs)
J. von Pawel, Jennifer F. Tseng, M. Dediu, C. Schumann +6 more
201517 citations
Semantic Scholar
Phase 2 HERALD study of patritumab (P) with erlotinib (E) in advanced NSCLC subjects (SBJs).
J. von Pawel, Jennifer F. Tseng, M. Dediu, C. Schumann +6 more
201414 citations
Semantic Scholar
P3.02b-045 Patritumab plus Erlotinib in EGFR Wild-Type Advanced Non–Small Cell Lung Cancer (NSCLC): Part a Results of HER3-Lung Study: Topic: EGFR Clinical
Luis Paz-Arez, P. Serwatowski, A. Szczesna, J. Pawel +8 more
201711 citations Open access
Semantic Scholar
A first-in-human phase I study of U3-1287 (AMG 888), a HER3 inhibitor, in patients (pts) with advanced solid tumors.
J. Berlin, V. Keedy, P. Jänne, L. Yee +6 more
2011Journal of Clinical Oncology9 citations
Semantic Scholar
Final reporting of a phase I clinical trial of the oral PPAR-gamma agonist, CS-7017, in patients with advanced malignancies.
M. Pishvaian, I. Cotarla, A. Wagner, J. Deeken +6 more
20105 citations
Semantic Scholar
A randomized, open-label phase II study of efatutazone in combination with FOLFIRI as second-line therapy for metastatic colorectal cancer (mCRC).
J. Marshall, D. Shuster, T. Goldberg, C. Copigneaux +12 more
20144 citations
Semantic Scholar
1336TiPPHASE (PH) 3 STUDY OF PATRITUMAB (P) PLUS ERLOTINIB (E) IN EGFR WILD-TYPE SUBJECTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC).
L. Paz-Ares, J. von Pawel, B. Moritz, J. Mendell +3 more
2014Annals of Oncology4 citations Open access
Semantic Scholar
1-anilino-naphthalene 8-sulfonic acid (ANS) as a probe for the binding of antidepressant drugs to human alpha 1-acid glycoprotein (AAG).
R. Zini, C. Copigneaux, J. Tillement
1989Progress in clinical and biological research4 citations
Semantic Scholar
Soluble heregulin, HER3 ligand, to predict the efficacy of anti-HER3 antibody patritumab combination with erlotinib in randomized phase II study, HERALD, for non-small cell lung cancer.
K. Yonesaka, K. Hirotani, J. Pawel, M. Dediu +3 more
20163 citations
Semantic Scholar
Abstract P4-16-09: Phase 1b/2 trial of the HER3 inhibitor patritumab (U3-1287) in combination with trastuzumab plus paclitaxel in newly-diagnosed patients with HER2+ metastatic breast cancer (MBC)
S. Carraro, D. Campos, C. Copigneaux, C. Saintilien +5 more
20132 citations
Semantic Scholar
Identification of a predictive biomarker for patritumab (P), an anti-HER3 monoclonal antibody, in advanced NSCLC.
Jeanne Mendell-Harary, J. Ruhe, Matthias Schneider, Wenqin Feng +7 more
20141 citations
Semantic Scholar
Abstract PR6: Phase 1b/2 trial of HER3 inhibitor U3-1287 in combination with erlotinib in advanced NSCLC patients (pts): HERALD study
J. von Pawel, Barbara Lueps, Jennifer F. Tseng, C. Copigneaux +1 more
2012Clinical Cancer Research1 citations
Semantic Scholar
Phase 3 study of patritumab plus erlotinib in EGFR wild-type subjects with advanced non-small cell lung cancer
L. Paz-Ares, J. von Pawel, B. Moritz, J. Mendell +3 more
20140 citations
Semantic Scholar
Abstract A187: A phase 1b/2 trial of U3–1287, a HER3 inhibitor, in combination with erlotinib in patients (pts) with advanced NSCLC.
Jennifer F. Tseng, B. Ebrahimi, T. Johnson, C. Copigneaux +2 more
20110 citations
Semantic Scholar
234 A phase 1, open-label, dose-finding study to assess the safety and tolerability of U3 1287 (AMG 888), a human monoclonal antibody targeting HER3 in patients with advanced solid tumors
P. LoRusso, V. Keedy, L. Yee, M. D. de Oliveira +6 more
20100 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

R. Beckman×8
Invite
R. Beckman — researcher profile on SciRah
J. von Pawel×8
Invite
J. von Pawel — researcher profile on SciRah
Xiao-Ping Jin×6
Invite
Xiao-Ping Jin — researcher profile on SciRah
Shu-Quan Chen×5
Invite
Shu-Quan Chen — researcher profile on SciRah

×4

Invite

T. Hettmann — researcher profile on SciRah

Invite

J. Mendell — researcher profile on SciRah

Invite

Wenqin Feng — researcher profile on SciRah

Invite

M. Dediu — researcher profile on SciRah

Jennifer F. Tseng×4

Invite

Jennifer F. Tseng — researcher profile on SciRah

Invite

B. Moritz — researcher profile on SciRah

Invite

N. Rizvi — researcher profile on SciRah

Invite

V. Keedy — researcher profile on SciRah